$PGNY

Scott Cheryl sold $196K of PGNY

Scott Cheryl sold 7,439 shares of Progyny, Inc. (PGNY) at $26.38 ($0.20M total) on 2026-06-01.

Original reporting
SEC EDGAR · Scott Cheryl
Published Jun 3, 2026, 8:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PGNY
Neutral
medium confidence
Mentioned
$PGNY
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGNYNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with any concurrent company news, but the filing itself is not a fundamental update.

02

Market read

Provides a dated insider sale datapoint that can marginally influence short-term sentiment around PGNY.

03

What to watch

No 10b5-1 plan is cited; however, Form 4s can still reflect pre-planned or non-informational motives, and the article lacks context on total insider holdings or prior sale frequency.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed 2026-06-03 (sale dated 2026-06-01)

Background

This is an SEC Form 4 insider transaction disclosure for a Progyny director, reporting an open-market sale of shares.

Company-level read

Ticker impact

$PGNYNeutralMedium confidence
Context

Progyny director Scott Cheryl sold 7,439 shares in an open-market transaction disclosed via SEC Form 4 on 2026-06-01.

Expected impact

Low likelihood of a sustained price move; any effect is likely limited to short-term sentiment/flow.

Evidence & confidence

The filing provides a realized sale price and size, but insider transactions alone rarely change near-term fundamentals without accompanying company-specific news.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity/tax-related and does not necessarily reflect a bearish view on Progyny’s prospects.

Key entities

  • Progyny, Inc.

    Subject of the SEC Form 4 insider sale disclosure.

  • Scott Cheryl

    Director who sold 7,439 shares; holdings after transaction were 19,772 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

$PGNYHigh

This fertility benefit business is set to boom. Buy the stock now, Wells Fargo says

Wells Fargo initiated coverage of Progyny with an overweight rating and $37 price target, implying 45% upside. The analyst cited demographic trends, corporate wellness focus, and healthcare innovation as drivers. Progyny's market share growth, global expansion, and new offerings were highlighted. Nine of 11 analysts rate the stock a buy or strong buy, with shares up 13% over the past year.

$PGNYMedAI 8/10

Progyny (PGNY) Q2 2026 Earnings Call Transcript

Progyny (PGNY) reported Q2 2026 revenue of $350.5 million, up 5.3% reported (11% excluding a transition agreement), and net income of $28.1 million ($0.34/diluted share). Adjusted EBITDA rose to $62.1 million, with gross margin expanding to 25.5%. Fertility benefit revenue was $230.2 million. Full-year 2026 guidance: revenue $1.36B to $1.385B, adjusted EBITDA $233M to $240M.

$PGNYMedAI 8/10

Progyny (PGNY) Q2 2026 Earnings Call Transcript

Progyny (PGNY) reported Q2 2026 revenue of $350.5M (+5.3% reported, +11% excluding a transition agreement), net income of $28.1M ($0.34/share), and adjusted EBITDA of $62.1M (17.7% margin). Fertility benefit revenue was $230.2M and pharmacy $120.3M. Guidance: 2026 revenue $1.36B-$1.385B and adjusted EBITDA $233M-$240M; Q3 revenue $335M-$345M.